Cefiderocol + Meropenem + Linezolid
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Healthcare-associated Pneumonia (HCAP)
Conditions
Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)
Trial Timeline
Oct 24, 2017 → Apr 1, 2019
NCT ID
NCT03032380About Cefiderocol + Meropenem + Linezolid
Cefiderocol + Meropenem + Linezolid is a phase 3 stage product being developed by Shionogi for Healthcare-associated Pneumonia (HCAP). The current trial status is completed. This product is registered under clinical trial identifier NCT03032380. Target conditions include Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03032380 | Phase 3 | Completed |
Competing Products
2 competing products in Healthcare-associated Pneumonia (HCAP)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Cefiderocol + Best Available Therapy | Shionogi | Phase 3 | 77 |
| Ceftolozane/tazobactam + Meropenem | Merck | Phase 3 | 77 |